Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granule + Niraparib in Ovarian Cancer
NCT05749211Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of huaier granule in ovarian cancer, sponsored by Ruijin Hospital. Primary endpoint: Progression Free Survival at 2 years. Planned start May 2023; status: not yet recruiting.
02
Drugs
huaier granule
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05749211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749211.